News

Nanostics Launches Clinical Utility Study for Its AI-Powered ClarityDX Prostate Test to More Accurately Identify Aggressive Prostate Cancer
The first patient was enrolled this month in a Nanostics-sponsored clinical utility study in Calgary to quantify the impact of incorporating ClarityDX Prostate into the standard of care for the ...
Renal & Urology News19h
Polygenic Risk Score May Have Clinical Utility for Prostate Cancer Screening
Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...
Blavity on MSN1d
Prostate Cancer Has A High Survival Rate But Is More Aggressive In Black Men – Here’s What To Know
Prostate cancer is one of the most common types of cancer that affects men. Understanding what it is, who is at risk and how ...
Clinical Advisor2d
MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer
HealthDay News — A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced genitourinary (GU) toxicity in patients ...